Clinical Trials Related to Multiple Myeloma

Related studies linked through entity extraction aliases.

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

Status: UNKNOWN
Phase: PHASE2

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Status: RECRUITING
Phase: PHASE2

A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma

Status: COMPLETED
Phase: PHASE1

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Status: RECRUITING
Phase: PHASE1

Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Cellular Therapy

Status: RECRUITING
Phase: NA

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

Status: COMPLETED
Phase: NA

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events

Status: COMPLETED
Phase: N/A

Isatuximab in Type I Cryoglobulinemia

Status: UNKNOWN
Phase: PHASE2

Descartes-25 in Relapsed/Refractory Multiple Myeloma

Status: TERMINATED
Phase: PHASE1

In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

Status: RECRUITING
Phase: EARLY_PHASE1

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

Status: RECRUITING
Phase: PHASE1/PHASE2

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Status: TERMINATED
Phase: PHASE2

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Stem Cell Translpantation in Multiple Myeloma

Status: COMPLETED
Phase: PHASE2

A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

Status: UNKNOWN
Phase: PHASE1/PHASE2

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma

Status: TERMINATED
Phase: PHASE1

Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy

Status: COMPLETED
Phase: NA

Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

Status: COMPLETED
Phase: PHASE2